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ABSTRACT
Background and Significance.
The leishmaniases are an important group of neglected tropical parasitic diseases caused
by parasitic protozoa of the genus Leishmania. International health authorities estimate that
350 million people around the world are at risk for contracting leishmaniasis. Two million new
cases occur each year and 12 million people are presently infected worldwide. Leishmaniasis is
endemic throughout the Americas region including all of Central America, most of South
America, Mexico and southern Texas. Leishmania is also considered a threat to the military
readiness of U.S. troops deployed to the Middle East or Latin America.
First- and second-line treatments for leishmaniasis are highly toxic. Drug resistance is on
the increase. Elimination of the sandfly vector and mammalian reservoirs has not proven
practical. For this reason, the World Health Organization has designated the development of an
effective leishmaniasis vaccine as a major global public health priority.
Leishmanization is the oldest form of vaccination against leishmaniasis which had been in
practice for hundreds of years. This practice was replaced later by an attenuated Leishmania
major vaccine, but severe side effects and complications had limited its use. Research and
technology have advanced into third generation vaccines, DNA vaccines. DNA vaccines are
stable at high temperatures and inexpensive to produce. However, they possess lower than
desired immunogenicity because of the degradation of DNA by DNAse before they reach the
target cells. Biopterin transporter (Bt), Intracellular adhesive molecule (ICAM), open reading
frames (ORFF), and Amastin are important molecules found in Leishmania amastigote or
promastigote stages. Previous studies have shown that Bt and ORFF can produce partial
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protection against experimental leishmaniasis. Therefore, the development of a method to
protect DNA until its delivery to the target cell, i.e., the Leishmania parasite, would be an
important scientific advance. Encapsulating DNA within a degradable delivery system such as in
nanoparticles could theoretically help to improve the delivery of leishmaniasis DNA vaccines to
target cells since degradation would be reduced.
Objectives.
The two major objectives of the Phase 0 experimental study were to: (1) describe the
immune response and side effects induced by a DNA vaccine candidate encapsulated within
metallo-lipid microparticles and (2) define protection generated by a DNA vaccine candidate
metallo-lipid microparticle against infection caused by Leishmania mexicana in murine models.
Hypothesis.
It is hypothesized that the use of a DNA delivery system incorporating copper or zinc
metallo-lipid microparticles will increase the immunogenicity of the DNA leishmaniasis vaccine
candidate by decreasing the amount of degradation that occurs prior to the delivery to the
target cells.
Methodology.
The experimental study was conducted using 6-week old female BALB/c mice. The mice
were randomized to one of seven groups. Group 1 (n=3) received pVAX-bt-icam-I(5µg) + pVAXorff-amastin(5µg)+ metallo-lipid Zinc 32ng (ML-Zn). Group 2 (n=3) received pVAX-bt-icam-I(5µg)
+ pVAX-orff-amastin(5µg)+ metallo-lipid Copper 32ng (ML-Cu). Group 3 (n=4) received pVAX-bticam-I(5µg) + pVAX-orff-amastin(5µg)+PBS. Group 4 (n=6) received pVAX-bt-icam-I(50µg) +
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pVAX-orff-amastin(50µg). Group 5 (n=4) received metallo-lipid Copper (ML-Cu). One control
group, Group 6 (n=6), received 100µL of PBS and the other, Group 7 (n=7), received only PVax.
Six weeks after the first vaccination, the mice were challenged with Leishmania mexicana
(106) in their right hind footpad. Footpad thickness was measured weekly for eight weeks. The
mice also were examined for potential adverse effects. Two aliquots of lymph nodes and
spleen cells from the sacrificed mice were used to analyze intracellular cytokine expression by
flow cytometry. Gene expression was analyzed using Quantitative Real Time Polymerase Chain
Reaction with TaqMan Probes (Interleukin-2, Interleukin-4, Interleukin-10, and Tumor Necrosis
Factor-α, Interferon- γ). Tissue samples from hind foot pad lesions were processed and plated
to determine the amount of parasites present per gram of tissue.
Results.
The study results suggested that a partial protective effect occurred in the pVAX-ORFFAmastin (5µg) + pVAX-Bt-ICAM (5µg) + ML-Cu and pVAX-ORFF-Amastin + pVAX-Bt-ICAM (100µg)
experimental groups. These groups had smaller mean footpad lesions compared to the control
group mice. In addition, the pVAX-ORFF-Amastin (5µg) + pVAX-Bt-ICAM (5µg) + ML-Cu group
had a Th1 cytokine profile (high IFN-γ, and low IL-4 and IL-10 with values of 27.5, 0, and 0.57 χfold more RNA copies than the calibrator sample, respectively. This type of pattern has been
reported as associated with immune protection against Leishmania infection.
Discussion.
The results of this study suggest that pVAX-ORFF-Amastin (5µg)+ pVAX-BtICAM(5µg)+ML-Cu is immunogenic and provides partial protection in the BALB/c mouse model.
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Further experimentation is needed to increase the immunogenicity of this candidate vaccine
such as increasing the concentration of the plasmid or ML-Cu microparticle.
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE
1.1 Epidemiology of Leishmaniasis
The leishmaniases are a group of vector-borne parasitic disease caused by protozoan
flagellates of the genus Leishmania (Chakravarty and Sundar, 2010; Dedet, 2002).
Leishmaniasis is widely distributed around the world. It currently threatens 350 million people
in 88 countries in five continents (Reithinger, 2007). Out of the 88 countries, 16 are
industrialized and 72 are developing countries. Thirteen of these are ranked among the
poorest in the globe (Shaw, 2002). Leishmaniasis can be found in Europe, Africa, Asia, South
America, Central America, and North America (Shaw, 2002). It is estimated that there are two
million new cases each year and it is responsible for 70,000 deaths per year (Murray et al.,
2005). There are currently 12 million people infected in the world (Reithinger, 2007).
1.2 Leishmania Species
There are approximately 25 different Leishmania species. These include Old World and
New World species that differ from each other regarding their molecular and biochemistry
characteristics (Reithinger et al., 2007). The Leishmania species found in the Old World are
Leishmania donovani (Africa, Asia), Leishmania major (Middle East, Asia, and Africa) Leishmania
infantum (Europe), and Leishmania tropica and aethiopica (Asia, Middle East, and Africa)
(Killick-Kendrick, 2002). These species cause cutaneous, visceral, and mucocutaneous
leishmaniasis (Killick-Kendrick, 2002). The Leishmania braziliensis complex (L. braziliensis, L.
panamensis, L. guyanensis, and L. peruviana) cause cutaneous and mucocutaneous
leishmaniasis (Shaw, 2002). The Leishmania mexicana complex (L. mexicana, L. amazonensis,
and L. venezuelensis) is the causative agent of cutaneous and diffuse leishmaniasis.
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The L. Mexicana complex has a wide distribution. L. mexicana is found from northern
Brazil to South-Central U. S. in Texas and Oklahoma (Bailey & Lockwood, 2007).
Leishmania is present in the New World from Brazil up through Central America,
Mexico, and South Central United States (CDC, 2008). In 2006, there were 62000 leishmaniasis
cases reported in the Americas region (PAHO, 2007). More than 5000 of these were visceral
leishmaniasis cases (PAHO, 2007). In 1903 there were 30 indigenous cases reported in the
southern part of Texas (Wright et al., 2008) and subsequently eight local cases of cutaneous
leishmaniasis were reported from 1970-1989 (Furner, 1990). From 2005-2007 there were nine
cases reported in the northern part of Texas around the Dallas-Fort Worth metroplex area
(Wright et al., 2008). Leishmaniasis is not considered to be endemic in Texas. However, these
findings do illustrate that both the vector and reservoir species are spreading into the United
States (Wright et al., 2008).
1.3 Clinical Manifestations
Leishmania parasites can cause four different clinical manifestations: cutaneous
leishmaniasis, mucocutaneous leishmaniasis, visceral leishmaniasis and diffuse cutaneous
leishmaniasis (Desjeux, 2004). Clinical severity primarily depends upon host immunity and the
parasite species involved (Murray et al., 2005).
Cutaneous leishmaniasis is predominantly caused by L. major in the Old World and by
many several species in the New World including L. mexicana being one of the most prevalent
(Desjeux P. , 1996). Cutaneous leishmaniasis is characterized by self-healing lesions at the site
of the sandfly bite (Pearson & Sousa, 1996). This clinical manifestation is limited to skin lesions
which, rarely penetrate into the subcutaneous tissues. Occasionally, it may affect deeper tissue
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such as mucus membranes, depending on the Leishmania species (Bailey & Lockwood, 2007).
Incubation periods range from a few days to months. The lesions vary from ulcerating to
smooth nodules, tend to be circular or oval, and are usually not larger than 10 cm in diameter
(Bailey & Lockwood, 2007). Typically, the sandfly bite will evolve into a nodule that will enlarge
and ulcerate which takes about one to three months (Murray et al., 2005). Active lesions and
permanent scar formation on exposed body parts such as hands and face are associated with
social stigma (Bern et al., 2008). Social stigmatization from this disease may cause anxiety,
depression symptoms, decreased body satisfaction and an overall diminished quality of life
(Yanik et al., 2004).
Mucocutaneous leishmaniasis is caused by L. brasiliensis, L. panamensis, and L.
guayanensis (Shaw, 2002). This infection is due to the migration of the parasite via blood or
lymph to the mucosal membranes such as the mouth, nasal passages, pharynx, and rarely the
genitals (Osorio et al., 1998). Clinical progression to this mucosal disease appears in 1-10% of
patients (David &Craft, 2009). When left untreated, these lesions can result in facial deformities
and is potentially life threatening (Bern et al., 2008; David and Craft, 2009).
Visceral leishmaniasis is caused by L. donovani, L. infantum, and L. chagasi (Pearson &
Sousa, 1996). Persons with this clinical form usually have symptoms such as fever, malaise,
weight loss (Pearson & Sousa, 1996). The incubation period may range from 10 days to 34
months, but is typically 3-8 months (Pearson & Sousa, 1996). The parasite attacks the liver
which causes hepatomegaly and splenomegaly (Pearson & Sousa, 1996). If left untreated,
infected individuals may develop diarrhea, tuberculosis, measles or other secondary infections
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in the late stages due to immunosupression (Pearson & Sousa, 1996). These are the most
frequent causes of death in individuals with active late-stage visceral disease.
The least common clinical manifestation is diffuse cutaneous leishmaniasis. There have
been documented cases in Latin America, the United States of America, and Africa (Convit et
al., 1972). Diffuse cutaneous leishmaniasis is predominantly caused by L.mexicana and rarely
by L. amazonensis (Shaw, 2002). Parasite filled nodules appear throughout the individual’s
body (Sinha et al., 2008). Inflammation of the lymph nodes in the neck, shoulder-blade and
groin areas are common in patients with this form (Convit et al., 1972). This clinical
manifestation appears to be more frequent among individuals with defective cell-mediated
immune responses (Desjeux, 2004). Relapse is inevitable (Desjeux P. , 2004).
1.4 Leishmaniasis Risk Factors
Leishmaniasis in the New World is considered an occupational disease due to the risk
associated with agriculture, mining, and oil industry work in endemic areas where the vector is
present (Desjeux, 1996). Other risk factors are migration, urbanization, co-morbidities
including HIV/AIDS, immunosuppression, and malnutrition can also affect the infection (Desjeux
P. , 2001; Sinha et al., 2005). Tourists and military personnel may also be infected when
traveling to endemic regions such as the Middle East and Latin America (Cardo, 2006). One risk
factor in endemic regions is blood contamination there have been a few leishmaniasis cases
described after organ transplant or blood transfusion (Cardo, 2006).
1.5 Leishmania Life Cycle
Leishmania parasites have a dimorphic life cycle which includes a promastigote and an
amastigote stage (Dumonteil et al., 2003). Figure 1 shows, the female sandfly becomes
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infected once it takes a blood meal from an infected mammal reservoir or human host (CDC,
2008). Female sand flies need protein with high biological value for the maturation of their
fertilized eggs which, they obtain from blood meals. Approximately eight hours after the blood
meal reaches the gut, Leishmania amastigotes transform into promastigotes (Olivier et al.,
2005). The promastigotes subsequently migrate up the alimentary tract of the sandfly where
they multiply by binary fission and live extracellularly (Mosser & Brittingham, 1997). Four to
five days later, the promastigotes travel up to the esophagus to the salivary glands of the
sandfly where they accumulate until the next blood meal (Sangueza et al., 1993). Once the
proboscis pierces the skin during the sandfly’s next feeding, the saliva containing anti-coagulant
and the promastigotes are introduced into the mammalian host (Pearson & Sousa, 1996). Once
inside the host, the promastigotes are engulfed by macrophages where they rapidly revert to
amastigotes, the obligate intracellular stage (Olivier et al., 2005).

Figure 1. (Leishmaniasis, 2009)
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1.6 Leishmania Morphology
The amastigote stage occurs in the host where the parasite is able to survive and
multiply inside macrophages. The amastigotes are usually two to five micrometers in length
(Garnham, 1971). Amastigotes tend to have a spherical shape; they multiply by binary fission,
and have an internalized flagellum (Garnham, 1971). Promastigotes are elongated in shape,
20µm in length, and have an external flagellum. These live inside the sandfly vector (Olivier et
al., 2005). Promastigotes also multiply by binary fission but division starts in the anterior
portion of the parasite (Garnham, 1971). The promastigote stage may be further divided into
the procyclic and infective metacyclic stages (Olivier et al., 2005). Pro-cyclic promastigotes
multiply in the gut. In contrast, the meta-cyclic promastigotes can be found in the mouthparts
and are infective (Olivier et al., 2005).
1.7 Leishmania Vector
The sandfly corresponding to Suborder Nematocera: Order Diptera: Family Psychodidae:
Sub-Family Phlebotominae is the Leishmania vector (Killick-Kendrick, 2002). The female sandfly
is the vector for all Leishmania species approximately 30 species of sand flies are documented
as Leishmania vectors (Desjeux P. , 1996). The Old World (Europe, Asia, and Africa) genera is
Phlebotomus is divided into 12 subgenera. The New World (North America and South America)
genera is Lutzomyia which is divided into 25 subgenera. All of these are proven vector species
that transmit Leishmania are in these two genera (Killick-Kendrick, 2002). Lutzomyia diabolica
and Lutzomyia anthophora have been identified as vectors for L. mexicana, and can be found in
Mexico and the United States (Gonzalez et al., 2010).
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1.8 Leishmania Reservoir
Reservoirs for Leishmania include rodents, sloths, primates, and carnivores (Saliba &
Oumeish, 1999). Leishmania major’s main reservoir is the great gerbil, Rhombomys opimus, in
Central Asia (Saliba & Oumeish, 1999). There are many species of rodents that serve as
reservoir for L. mexicana. One of the primary hosts found in Mexico and Belize is Ototylomys sp
(Saliba & Oumeish, 1999). Secondary hosts belong to the genera Heteromys, Nyctomys,
Oryzomys, and Sigmodon (Saliba & Oumeish, 1999). The wood rat, Neotoma micropus, is
reported as a reservoir found in Texas (Saliba & Oumeish, 1999). Neotoma mexicana is found in
northern parts of Mexico and in the United States and is also believed to be a reservoir host for
L. mexicana (Gonzalez et al., 2010).
1.9 Leishmaniasis Diagnosis
Definitive diagnosis procedures use tissue samples which, are either acquired by
scraping or biopsy taken from the edge of the lesion which do not exacerbate the ulcerated
lesion (Bailey & Lockwood, 2007). The tissue samples can be stained with Giemsa at a pH of 6.8
in order to look for Leishmania amastigotes (Roussel et al., 2006; Desjeux, 1996). Polymerase
chain reaction (PCR) tests can also be performed on the DNA obtained from tissue samples and
have shown high specificity and high sensitivity which enables a scientist to do a species specific
diagnosis in a few hours (Berman,1997).
1.10 Leishmania Treatment
The first-line treatment for leishmaniasis recommended by the World Health
Organization (WHO) is pentavalent antimony. This drug is administered by injection via
parenteral, intramuscularly or intravenously (Reithinger et al., 2007). This treatment has
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potentially toxic side effects including musculoskeletal pain, renal failure, hepatotoxicity and
cardiotoxicity. It is not recommended for pregnant and breastfeeding women, very young
children, and individuals with some chronic illnesses (Reithinger et al., 2007). Misuse of firstline antileishmanial drugs has lead to parasite resistance (Chakravarty & Sundar, 2010; Berman,
1997).
An alternative injectable treatment is amphotericin B which is administered by i.m.
injection (Reithinger et al., 2007). The drug a fungizone with toxic side effects, is usually given
to patients who do not respond to the pentavalent antimony treatment (Berman, 1997).
Pentamidine is also administered by injection via parenteral and is prescribed at 2mg/kg on
alternate days for seven doses, which also has toxic side effects (Soto-Mancipe et al., 1993; Lai
A Fat et al., 2002). Other treatments are topical creams such as paromomycin which is
prescribed for cutaneous leishmaniasis (Croft & Yardley, 2002). An application of twice daily on
the lesion from 10 to 20 days and was seen to be effective towards cutaneous leishmaniasis
(Croft & Yardley, 2002). Alternative oral treatments are miltefosine and ketoconazole which
are prescribed for treating Old World visceral and cutaneous leishmaniasis (Saenz et al., 1990;
Soto et al., 2004). Miltefosine is an oral treatment prescribed as 2.5 mg/kg for duration of 28
days and has limited toxic-side effects, but less effective for New World cutaneous
leishmaniasis (Soto et al., 2004). The available first-line and second-line drugs for leishmaniasis
have severe toxic side effects; thus, the prevention through the use of a vaccine would be the
best strategy.
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1.11 Leishmania Molecules
Leishmania parasites appear to possess several different survival mechanisms. The
metacyclic promastigotes have long branched lipophosphoglycans (LPG) on their surface which
seems to prevent the attachment of C5b-C9 and avoids complement driven lysis (Beverley &
Turco, 1998; Olivier et al., 2005). Another surface molecule present on the amastigote surface
is a glycoprotein (Gp63) that has been shown to help in amastigote survival (Olivier et al.,
2005). The most abundant surface molecule on the promastigote stage is glycosylinositol
phospholipid (GIPL). This molecule has a short length and a long half-life which has been
suggested as capable of defending parasites against proteolytic damage (Olivier et al., 2005).
Other important molecules found in Leishmania species are Biopterin Transporter (BT),
intracellular adhesive molecule (ICAM), open reading frames (ORFF), and amastin. The
biopterin transporter gene is responsible for encoding the transport of biopterin an essential
nutrient into the parasite (Landfear, 2002). This gene also has shown partial protection against
leishmaniasis when used as a vaccine (Papadopoulou, 2002). ICAM was first described in L.
amazonensis (Chiang et al., 2002). It is present on the parasite surface in the promastigote
stage as well as in the nucleus (Chiang et al., 2001). The ORFF gene was first described in L.
donovani by Myller (Myller et al., 1994). This molecule has protein coding functions which
confer an advantage in parasitic growth and survival (Ghosh et al., 1999). Amastin is present
during the intracellular amastigote stage of the parasite life cycle (Rochette, 2005). It plays a
role in proton or ion traffic across the cellular membrane in order to adjust cytoplasmic pH (Wu,
2000).
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1.12 Leishmania Immunology
Both Th1 and Th2 immune responses are activated during Leishmania sp. Infection.
Each of these stimulate the production of different cytokines (Heinzel, 1991). Immunity against
leishmaniasis occurs through the stimulation of Th1 cells to produce lymphokines including
interferon-gamma (IFN-γ), interleukin-12 (IL-12), and tumor necrosis factor-alpha (TNF-α)
(Scott, 1988, Liew, 1990). These activate macrophages to destroy intracellular amastigotes
(Scott, 1988, Liew, 1990). Interleukin-2 (IL-2), produced by Th1 cells, causes macrophage
activation indirectly by stimulating the secretion of IFN-γ (Murray, 1993). This autocrine also
makes Th1 immune response more efficient. The suppressive Th2 immune response produces
IL-4, IL-5, IL-6, and IL-10 which downregulate Th1 immunity. Macrophages are thus unable to
effectively kill the intracellular amastigotes; this allows Leishmania survive and replicate within
phagolysosomes of resident macrophage resulting in disease chronicity (Liew, 1989).
1.13 Experimental Leishmaniasis Vaccines
The evidence indicates that once an individual has been infected with pathogenic
species of Leishmania they develop resistance to subsequent infection (Reithinger et al., 2007).
This suggests anti-Leishmania vaccines would be a feasible prevention method (Reithinger et
al., 2007). There are no current approved vaccines against any form of leishmaniasis for human
use. However, a number of different experimental vaccines are being tested (Handman, 2001).
Leishmanization is the oldest form of vaccination against leishmaniasis (Dunning, 2009). It
produces strong subsequent immunity to the disease (Dunning, 2009). Leishmanization
involves inoculating virulent Leishmania from a cutaneous lesion into a less visible area of the
body in order to prevent multiple lesions to the face or other exposed regions of the body
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(Dunning, 2009). Large scale vaccination trials using attenuated L. major were conducted in the
1970s and 1980s in Israel, Iran and the Soviet Union where a higher than expected number of
complications such as psoriasis, immunosuppression and large persistent lesions were observed
in inoculated patients (Dunning, 2009). This experience caused a search for new strategies
using whole parasites for vaccine trials against leishmaniasis (Dunning, 2009). A live vaccine is
still in use in Uzbekistan which is a mixture of L. major and killed parasite which decreases its
virulence (Noazin et al., 2008). A clinical trial done in Colombia against American cutaneous
leishmaniasis with a killed whole-cell L. amazonensis candidate vaccine did not offer any
protection (Velez et al., 2005). A cocktail of killed L. braziliensis, L. guyanensis, and L.
amazonensis vaccine with BCG adjuvant was used in a study in Ecuador against cutaneous
leishmaniasis and produced a 72.9% protective efficacy (Armijos et al., 1998).
There is also a fucose mannose ligand (FML) vaccine that induced protection for up to
three and a half years against canine visceral leishmaniasis in Brazil (Borja-Cabrera et al., 2004).
A protein purified vaccine, dp72, isolated from Leishmania donovani promastigotes showed
partial protection in BALB/c mice when infected with L. donovani and L. major (Rachamim &
Jaffe, 1993). Loss of potency and stability during transportation for second generation vaccines
has lead research into third generation vaccines (DNA vaccines) which are more stable
(Palatnik-de-Sousa, 2008).
1.14 DNA Vaccines
DNA vaccines are relatively simple and inexpensive to produce (Sasaki et al., 2003).
Genes are inserted into a plasmid and once injected are read by the target cells, and in turn,
produces proteins. These proteins are foreign to the body and will be destroyed by
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macrophages and natural killer cells (Xiang et al., 2010). They will be recognized by T-cells
which will then produce memory T-cells (Xiang et al., 2010). These will be able to identify the
pathogen if the individual’s immune system is attacked by it (Xiang et al., 2010). Such vaccine
candidate can effectively engage both major histocompatibility class (MHC) I and MHC II
pathways that activate both CD8+ and CD4+ T cells (Khamesipour et al., 2006). DNA vaccines
are also stable at high temperatures and safer as they do not contain virulent Leishmania
pathogens (Dumonteil, 2007).
DNA vaccine research has been tested against Leishmania. Anti-L. mexicana DNA
vaccines that encode for GP63, CPb, LACK and GP46, present in L. amazonensis, were used and
evaluated in BALB/c mice (Dumonteil, 2003). Dumonteil and his colleagues reported partial
protection against infection with each separate vaccine (Dumonteil, 2003). The protection was
further increased when a mixture of the GP63, CPb, and GP46 vaccines were administered to
the mice suggesting that these three antigens would be good candidates in DNA vaccines
against L. mexicana (Dumonteil, 2003). Substantial protection was seen against L. donovani
with a DNA vaccine using ORFF as an antigen (Sukumaran et al., 2003). Another study that
used PSA-2 as an antigen in a DNA vaccine against L. major also showed significant protection
against infection; but, the antibody levels were miniscule (Dumonteil, 2003).
1.15 Nanocarriers for Vaccine Delivery
DNA and recombinant protein vaccines are quite effective but lose immunogenicity due
in part to the presence of DNase (Shahiwala et al., 2007). In order to increase immunogenicity
there is a need for safe adjuvants and/or delivery systems that can be used for DNA vaccines
(Shahiwala et al., 2007). An effective nanocarrier needs to protect the DNA in the vaccine from

12

extracellular and intracellular degradation and accommodate large plasmids (Xiang et al., 2010).
Different nanocarrier delivery systems have been designed in order to provide effective
immunization by enhancing an antibody response at the cellular level (Shahiwala et al., 2007).
Liposomes, dendrimers, micro and nano particles, emulsions, micelles, and immunostimulating
complex (ISCOMs) have been used as delivery systems against pathogens (Xiang et al., 2010).
Liposomes are organized phospholipid vesicles that have been used to encapsulate
protein and DNA vaccines and increase the immune response (Shahiwala et al., 2007). The
mechanism by which liposomes enhance the adjuvant properties is not well understood but
their interaction with macrophage and dendritic cells after the activation of the complement
system could be a major factor (Shahiwala et al., 2007). There is a developed liposomal vaccine
against Tetanus toxoid that was found to be effective in inducing mucosal immunity (Tafaghodi
et al., 2006).
Nanoparticle complexes are used to target dendritic uptake and have been shown to
improve immunogenicity (Xiang et al., 2010). A study using micro-particles and nanoparticles
encapsulated with Toxoplasma gondii tachyzoites used as an intranasal vaccine showed
increased levels and higher mucosal and systemic immunity (Stanley et al., 2004).
Dendrimers are synthetic polymers that have a branched shape (Boas Heegaard, 2004).
These have been shown to increase immune response against influenza (Boas Heegaard, 2004).
Small & amounts of dendrimers have been shown to be effective adjuvants for influenza and do
not cause toxic complexes (Shahiwala et al., 2007). These polymers have also been reported as
effective in increasing an immune response against renal cell cancers (Shahiwala et al., 2007).
Immunostimulating complexes (ISCOM) are open complexes that usually have a diameter of 30-
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80 nm and are made up of phospholipids, cholesterol, immunogen, and saponin (Sun et al.,
2009). When ISCOMs are used as vaccine adjuvants they produce a broad immune response
such as high T cell response and increased antibody levels (Sun et al., 2009). These studies
suggest that nanocarriers can be effective in increasing immunity against pathogens.
1.16 Study Rationale
There has yet to be an effective preventative vaccine against cutaneous leishmaniasis.
Most of the experimental naked DNA vaccines have shown poor immunogenicity mainly
because they undergo massive degradation immediately after being inoculated into
experimental animals and before reaching target cells. Therefore, the development of an
efficient system for DNA delivery is needed. A metallo-lipid microparticle delivery system may
be an effective alternative in increasing DNA vaccine immunogenicity because it encapsulates
the DNA and protects it from DNase until it reaches the target cells in the mouse.
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CHAPTER 2: STUDY AIMS AND HYPOTHESIS
2.1 Hypothesis
It is hypothesized that the use of a DNA delivery system incorporating copper or zinc
metallo-lipid microparticles will increase the immunogenicity of the DNA leishmaniasis vaccine
candidate by decreasing the amount of degradation that occurs prior to the delivery to the
target cells.

2.2 Study Objective
The overall objective of the proposed experimental study is to determine the efficacy of
pVAX-Bt-ICAM and pVAX-orff-Amastin plus metallo-lipid microparticles in preventing murine
leishmaniasis caused by Leishmania mexicana.
The specific aims of the study are:
1. To describe the immune response and side effects induced by a DNA vaccine
candidate encapsulated within metallo-lipid microparticles.

2. To define protection generated by a DNA vaccine candidate metallo-lipid
microparticle against infection caused by Leishmania mexicana in a susceptible BALB/c
murine model.
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CHAPTER 3: METHODS AND MATERIALS
3.1 Study Design
The study design was an experimental Phase 0 study.
3.2 Study Approvals
This study protocol was approved by the UTEP Institutional Biosafety Committee
recombinant DNA Protocol (IBC) on March 14, 2005 (Protocol #2005-02) and by the UTEP
Institutional Animal Care and Use Office on September 7, 2006 (Protocol # A-200606-3).
3.3 Study Funding Source
UTEP ORSP URI Program. January 2008.
3.4 Metallo-Lipid Carrier
The zinc and copper lipids were synthesized as follows: Compound 1,4,7
tricyclontriazacyclononame was reacted with 1-bromododecane. Then a substitution reaction
using tetralaydrofuran solvent was placed in the reaction and left in reflux for 48 hours. The
solvent was subsequently purified using column chromatography with 90% chloroform and 10%
methanol. The reaction was conducted in acetylnitrile with two equivalents of the
functionalized 1,4,7-tricyclontriazacyclononame and one equivalent of Cu(OTF)2. The reaction
1,4,7-tricyclontriazacyclononame was added by drops to Cu(OTF)2 for one hour. This reaction
was carried out in room temperature in an inert atmosphere consisting of nitrogen or argon. In
order to transform the complex into the liposomes, a solution of 1mM concentration in water
along with the complex was sonicated with 100 µL of chloroform to generate emulsification.
Finally, the sonicated solution was rotovaped to get rid of the chloroform.
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3.5 Cytotoxicity Assay
The copper and zinc metallo-lipids were tested using U-937 (ATCC) cells provided by the
UTEP Human Immunology and Nutrition Research Laboratory. The cells were cultured in RPMI1640 medium (Sigma-Aldrich) containing 2mM glutamine, 200 µg ml-1 penicillin, 10% fetal
bovine serum and 100µg ml-1 streptomycin and maintained at 37 degrees in 5% humidity CO2
atmosphere. In order to estimate 50% lethal dose (LD50) the [3H]-thymidine DNA labeling

micromethod was used. The cells were counted and plated twice in triplicate at a
concentration of 2.5 x 105 cells /well. Each metallo-lipid was dissolved in PBS and a different
concentration from 2-256 nM/well of the lipids was added to the cells. The cells were
incubated for 48 hours during which the last 18 hours were pulsed with 1 µCi of [3H]-thymidine
(GE Healthcare Life Sciences: Amersham) and then were harvested on glassfibre filters. The
[3H]-thymidine incorporation was determined by liquid scintillation with a beta-liquid
scintillation counter (Perkin Elmer Tri-carb2900tr).
3.6 Vaccine Design
The experimental leishmaniasis vaccine used was comprised of the antigens Biopterin
Transporter (BT), Intracellular Adhesive Molecule (ICAM), Amastin, and Open Reading Frames
(ORFF).
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pVAX-BT-ICAM vaccine
pVAX-orff-Amastin vaccine
Figure 2. Bicistronic Plasmids for the Experimental Leishmaniasis Vaccine.
The CMV served as the promoter region for BT, ORFF and the IRES cassette assured the
adequate expression of ICAM and Amastin. The restriction sites used to insert the Leishmania
gene segments and IRES cassette are NEH-I, BAM H1, PST-1 and XBA-1. BGHpA acted as the stop
codon and pUCORI acted as the start codon. Kanamycin resistant gene is used for plasmid
selection in E. coli.
3.7 Study Protocol
A total of 33 six week old female BALB/c mice purchased from Jackson Laboratory were
used and maintained under pathogen-free conditions. Leishmania mexicana LV4 strain was
provided by Dr. Eric Dumonteil from the Universidad Autonoma de Yucatan-Merida. The LV4
strain was isolated from a human cutaneous leishmaniasis case from Belize.
3.8 Immunization Protocol
As shown in Table 1. The mice were randomized to one of seven experimental groups.
Mice in the seven study groups were injected with a volume of 100 µl via intra-muscular in the
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hind leg quadriceps using a one mL BD syringe with the cocktail vaccine. All of the mice were
injected three times with the vaccine assigned to each group as illustrated in Table 1.
Table 1. Immunization Groups
Group
(No. of mice)
1 (n=3)

Plasmid

Metallo-lipid

pVAX-bt-icam-I(5µg) + pVAX-orff-amastin(5µg)

ML-Zn (32ng)

2 (n=3)

pVAX-bt-icam-I(5µg) + pVAX-orff-amastin(5µg)

ML-Cu (32ng)

3 (n=4)

pVAX-bt-icam-I (5µg) + pVAX-orff-amastin +PBS (5µg)

-

4 (n=6)

pVAX-bt-icam-I (50µg) +pVAX-orff-amastin (50µg)

-

5 (n=4)

-

6 (n=6)

- (PBS 100µl)

-

7 (n=7)

-(pVAX 100µl)

-

ML-Cu (32ng)

3.9 Challenge Infection and Lesion Measurement
After the third immunization, the mice were challenged in the right hind footpad with
Leishmania mexicana promastigotes (10x6) in the infective meta-cyclic stage. Mouse footpads
were measured for thickness with a digital caliper weekly for two months. Both hind legs were
measured in order to compare swelling size in the inoculated right hind leg and the left hind leg
without infection.
3.10 Adverse Vaccination Side Effects
During the eight week time frame after the mice were challenged with the parasite any
detectable side effects were recorded. Mice were observed and checked for visible weight
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change, posture, loss of fur on their backs, and lethargic behavior. Food and water intake were
also observed during this time frame.
3.11 Immunogenicity Determination
Mice were euthanized CO2 inhalation in order to compare the cellular immune
responses of the different experimental groups. The mice were dissected and the spleen and
hind leg lymph nodes were extracted. The spleen and lymph nodes were immediately
processed by grinding the tissue and cleaning the cells before plating them in a 96-well plate.
In order to clean the spleen cells, the homogenized tissue was transferred to a 50mL conical
tube where 5mL of 1X RBC Lysis buffer from eBiosciences was added and incubated at room
temperature for four minutes. To stop the reaction, 20-30mL of 1X PBS was added and then
the cells were centrifuged for 10 minutes at 1500 RPM in a refrigerated centrifuge (Beckman
Coulter Allegra X-12R). The supernatant was removed and one milliliter of fresh media, RMPI
media with 35mL of FBS and 500 µl of streptomycin, was added. The processing of the lymph
node cells was performed as follows. Tissues were homogenized and transferred to a 15 mL
conical tube in order to remove any solids from the tube. The homogenized tissue was
centrifuged for one minute. The supernatant was removed and fresh media was added to the
pellet. The lymph node and spleen cells were counted using a hemacytometer in order to
assure sufficient (10x6) cells per well.
3.12 Quantitative Real Time PCR (QRT-PCR) Procedure
The rest of the cells which were not used for the 96-well plates were processed in order
to extract RNA with the Ambion Ribo Pure Isolation of High Quality Total RNA kit (Applied
Biosystems). The RNA concentration was measured using a NanoDrop 1000 V3.5.2 (Nanodrop
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Technologies). After measuring the concentration, the RNA was processed into cDNA using the
High-Capacity cDNA Reverse Transciption Kit (Applied Biosystems).
Quantitative Real Time Polymerase Chain Reaction (QRT-PCR) was used to quantify
selected cytokines (IL-2, INF-y, IL-4, TNF-α, and IL-10) using TaqMan probes (Applied
Biosystems). Beta-actin was used as the reference gene. Complementary DNA (cDNA) was
plated into a PCR plate. Each well in the plate had 500ng of RNA, 1 μL TaqMan probe, 10 μL
TaqMan Universal Master Mix. The addition of nuclease free water brought the total volume in
each well to 20 μL. For the analysis the PCR plate was placed in an iCycler iQTM Optical Module
thermal cycler (BioRad).
Table 2.
QRT-PCR Thermal Cycler Program
Cycle 1 (1 cycle)

Temperature
Time

Cycle 2 (45 cycles)

I

I

II

50oC

95oC

60oC

3 minutes

10 seconds

60 seconds
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CHAPTER 4: STATISTICAL ANALYSIS
Data are presented as mean+ SEM. Data obtained from the QRT-PCR was analyzed by
normalizing relative quantification using β-actin as the reference gene and the 2-ΔΔCT (Livak)
Method which produces normalized expression ratios. Descriptive analysis was used for the
footpad swelling for the eight week time frame and for the QRT-PCR results.
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CHAPTER 5: RESULTS
5.1 Metallo-Lipid Synthesis and Transfection.
The copper and zinc metallo-lipid microparticles were first synthesized (Fig.3). In order
to ensure that the plasmid DNA vaccine was encapsulated within the microparticles, a gel
electrophoresis was conducted. As seen in figure 4 the first well is a control, the second and
third wells show the DNA with a low volume of the zinc microparticle and the last four wells
show the plasmid DNA vaccine with higher volumes of the zinc microparticle. Full
encapsulation of the plasmid DNA vaccine was visualized with 65µl of the copper microparticle
and 40µl of the zinc microparticle.
1

Figure 3. Metallo-lipid-Cu2+

2

3

4

5

6

7

Figure 4. Gel electrophoresis

In order to visualize gene expression T291 cells were transfected with pEGFPN1,
containing a green fluorescent protein gene plus the metallo-lipids-Cu2+ and Zn2+. As seen in
figures 5A and 5B the transfected cells expressed the green fluorescent protein at a
transfection efficiency of 39%.
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Figure 5A. T291 cells transfected with
pEGFPN1 plus metallo-liposome-Zn2+

Figure 5B. T291 cells transfected with
pEGFPN1 plus metallo-liposome-Cu2t

5.2 Cytotoxicity Assay.
Copper and zinc metallo-lipids cytotoxicity was evaluated using U-937 cells. The LD50
was shown to be 24mM/24nM for both the copper and zinc metallo-lipids. As is illustrated in
Figure 6 A&B, copper and zinc appear to be relatively non-toxic. Based on these experiments it
was decided they were safe to use as transporters at concentrations below 32ng.
Cytotoxicity Activity of Metallo-Liposome Cu, 48H Culture

Cytotoxicity activity of Metallo-Liposome Zn, 48h Culture
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Figure 6 A. Cytotoxicity Assay for Zn.
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Figure 6 B. Cytotoxicity Assay for Cu.
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Figure 7A. Mean difference in lesion development between groups 3, 5, 6, and 7
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Figure 7B. Mean difference in lesion development between groups 4, 5, 6, and 7
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Figure 7C. Mean difference in lesion development between groups 1, 2, and 6

5.3 Protection Against Infection.
Evaluations were carried out in order to determine whether the DNA vaccine was able
to induce protection against infection with L.mexicana. Immunized mice were challenged with
an injection of 106 L. mexicana metacyclic promastigotes in the right hind footpad, and both
infected and contra lateral footpads were measured for a total of eight weeks. At eight weeks
group 3 (pVAX-Bt-ICAM [5µg]+pVAX-ORFF-Amastin[5µg]+PBS) and group 4 (pVAX-BtICAM[50µg]+pVAX-ORFF-Amastin[50µg]) had the smallest mean difference footpad swelling
between the infected and contra lateral footpad (Fig. 7, A-B). As Figure 7B shows group 5
(Copper [32ng]) had the largest mean difference between hind footpads at eight weeks after
parasite challenge. Group 1 (pVAX-Bt-ICAM[5µg]+pVAX-ORFF-Amastin[5µg]+ML-Zn[32ng]) and
group 2 (pVAX-Bt-ICAM[5µg]+ pVAX-ORFF-Amastin[5µg]+ML-Cu[32ng]) were both similar in
mean difference of footpad swelling at the end of the eight weeks (Figure 7C). Also shown in
Figure 7A and 7B, the control groups 5 (Copper [32ng]), 7 (pVAX) and 6 (PBS) had the highest
mean difference in footpad swelling as was expected.
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A

B
C

Figure 7D. A (pVAX-Bt-ICAM-I
+ pVAX-ORFF-AMASTIN (10µg)
+ML-Zn) B (pVAX-Bt-ICAM-I +
pVAX-ORFF-AMASTIN (10µg)+
ML-Cu)

D

Figure 7E. C (pVAX-BtICAM-I + pVAX-ORFFAMASTIN (10µg)+PBS)
D (ML-Cu)

E

F

Figure 7F. E (pVAX-BtICAM-I + pVAX-ORFFAMASTIN (100µg)) F PBS

Partial protection is seen in the mice footpads in figure 7F where group 4 [E] (pVAX-Bt-ICAM-I +
pVAX-orff-AMASTIN (100µg) does not have a lesion as compared to control group 6 that has a
lesion.
5.4 Quantitative Real Time-Polymerase Chain Reaction.
We evaluated the spleen and lymph node cells with select cytokines, IL-2, IL-4, IFN-γ,
TNF-α, and IL-10, by quantifying and analyzing them through the use of TaqMan probes and
used β-actin as the reference gene.
5.4.1 Lymph Node Cells.
Group 1 [pVAX-Bt-ICAM (5µg) + pVAX-ORFF-Amastin (5µg) + ML-Zn (32ng)] shows a
mixed Th1 and Th2 immune response with elevated levels of IFN-γ and IL-10 suggesting disease
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progression (Figure 8A). Figure 8B illustrates group 2 ([pVAX-Bt-ICAM (5µg) + pVAX-ORFFAmastin (5µg) + ML-Cu (32ng)] having Th1 immune response with high levels of IFN-γ. Group 3
[pVAX-Bt-ICAM (5µg) + pVAX-ORFF-Amastin (5µg) + PBS] showed a mixed Th1 and Th2 immune
response with elevated levels of IL-4, IL-10, and IFN-γ (Fig. 8C). Group 4 [pVAX-Bt-ICAM (50µg)
+ pVAX-ORFF-Amastin (50µg)] which is shown in Figure 8D, suggests a mixed Th1 and Th2
immune response. Groups 5[copper (32ng)], 6(PBS), and 7(pVAX) all illustrated a mixed Th1 and
Th2 immune response as is illustrated in (Fig. 8, E-G).

Lymph Node: pVAX-Bt-ICAM(5µg) & pVAX-ORFFAmastin(5µg)+ ML-Zn(32ng)
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Figure 8A.

Lymph Node: pVAX-Bt-ICAM(5µg) & pVAX-ORFFAmastin(5µg)+ML-Cu(32ng)
Mean 2-∆∆CT

1.5
1
0.5

Mean

0
IL-2

IL-4

IFN-γ
TaqMan Probes

Figure 8B.
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Lymph Node: pVAX-Bt-ICAM(5µg)& pVAX-ORFFAmastin (5µg)+ PBS
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Figure 8C.

Lymph Node: Pvax-Bt-ICAM+Pvax-ORFF-Amastin(100ug)
70
Mean 2-∆∆CT

60
50
40
30
20
10
0
IL-2

IL-4

IFN-γ

Cytokines

Figure 8D.
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Figure 8F.
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5.4.2 Spleen Cells.
As Figure 9A illustrates group 1 [pVAX-Bt-ICAM (5µg) + pVAX-ORFF-Amastin (5µg) + MLZn (32ng)] has a slightly mixed Th1 and Th2 immune response with Th2 being predominant with
higher levels of IL-4, IL-10 in comparison to IFN-γ and TNF-α levels. Group 2 [pVAX-Bt-ICAM
(5µg) + pVAX-ORFF-Amastin (5µg) + ML-Cu (32ng)] displayed a typical Th1 immune response as
is shown in Figure 9B. Group 3 [pVAX-Bt-ICAM (5µg) + pVAX-ORFF-Amastin (5µg) + PBS]
displayed a mixed Th1 and Th2 immune response with elevated levels of IL-2, IL-4, IFN-γ, and IL10 (Fig. 9C). Group 4 [pVAX-Bt-ICAM (50µg) + pVAX-ORFF-Amastin (50µg)] in Figure 10D
illustrates a mixed Th1 and Th2 immune response with elevated levels of IL-2, IFN-γ and IL-10.
Groups 5[copper (32ng)], 6 (PBS), and 7 (pVAX) all have a mixed Th1 and Th2 immune response
with high levels of IL-10 which suggests disease progression (Figures 9, E-G).

Spleen: Pvax-Bt-ICAM (5µg)+Pvax-ORFF-Amastin(5µg)+MLZinc(32ng)
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Figure 9A.
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Spleen: pVAX-Bt-ICAM(5µg) & pVAX-ORFF-Amastin
(5µg)+ ML-Cu(32ng)
Mean 2-∆∆CT

5

4
3
2
mean

1
0
IL-2

IL-4

IFN-γ

TNF-α

IL-10

TaqMan Probes

Figure 9B.
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Figure 9C.

Pvax-Bt-ICAM+Pvax-ORFF-Amastin (100µg)
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Figure 9D.
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Figure 9F.
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5.5 Limitations
Sample size per group was very small; therefore, when running statistical analysis power
was not high enough to have statistical significance. Multiple samples were not read during the
QRT-PCR due to low cDNA concentrations.
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CHAPTER 6: Discussion
This Phase 0 study evaluated the immune response and protection induced by the DNA
vaccine (pVAX-Bt-ICAM+ pVAX-ORFF-Amastin) against L. mexicana infection with cu(II) and
zn(II) microparticle delivery systems. This is the first study to incorporate these four genes,
found on promastigotes and amastigotes, into bicistronic plasmids in a vaccine against L.
mexicana. A major finding of the present study is that pVAX-Bt-ICAM (5µg) + pVAX-ORFFAmastin (5µg) +ML-Cu displayed immunogenicity and provided partial protection in BALB/c
mice. This was illustrated with the Th1 (increased levels of IFN-γ and TNF-α) immune response
in the spleen and a lower mean difference in footpad thickness than our control groups (Group
5 Copper, Group 6 PBS, Group 7 Pvax). Elevated levels of IFN-γ promote inflammation and
activate macrophages which in turn kill Leishmania through the use of nitric oxide. Studies
have shown that the induction of a Th1 immune response against leishmania correlates with
protection in vaccinated mice (Handman, 1995). Moreover other studies have shown that
weak Th1 immune responses are sufficient to show protection against L. major (Sjolander et al.,
1998; Uzonna et al., 2004). As previously mentioned before Group 4 (pVAX-Bt-ICAM+ pVAXORFF-Amastin (100µg)) displayed a mixed Th1 and Th2 immune response which shows that at
the beginning of the trial it had a high Th1 immune response and at some point during the trial
the immune response decreased thus increasing levels of IL-10 were present due to disease
progression. Group 3 pVAX-Bt-ICAM+pVAX-ORFF-Amastin(10µg) displayed a prominent Th2
immune response in both spleen and lymph node cells; however, the mean difference for
Group 3 and 4 in footpad thickness was the lowest out of the seven groups. This clinically
displays partial protection as is seen in Figure 7E suggesting that the DNA vaccine is
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immunogenic and provides partial protection in murine models. From the footpad thickness
results the RT-PCR results had been expected to show intracellular cytokines to display a
prominent Th1 immune response which would correlate with the protection against L.mexicana
but rather a mixed Th1/Th2 and a prominent Th2 (increased levels of IL-4 and IL-10) immune
response was illustrated. The prominent Th2 immune response shows that the infection is at
systemic level as opposed to a mixed Th1/Th2 response which exhibits the infection at a
localized level. Elevated levels of IL-4 promote a Th2 immune response which has no
microbicidal effect against leishmania, thus promoting disease progression. High levels of IL-10
down regulate Th1 cytokines which inactivates macrophages. As was seen in this study there
were mice groups with elevated levels of IL-10 which, indicate disease progression which is due
in part to the inactivation of macrophages and Th1 by IL-10. Disease progression was also due
to the BALB/c mice because of their susceptibility to leishmaniasis. Additionally other studies
have shown that production of IL-10 impedes IFN-γ from activating macrophages; therefore,
preventing them from killing the Leishmania parasites (Kane and Mosser, 2001). Group 6 (PBS)
illustrated the natural evolution of a cutaneous leishmaniasis infection. This particular strain of
mice, BALB/c, are also extremely susceptible to leishmaniasis therefore a Th2 immune response
increases as is seen in Group 6.
6.1 Conclusion
This Phase 0 study suggests that the DNA vaccine pVAX-Bt-ICAM + pVAX-ORFF-Amastin
at a concentration of 100µg and when combined with the ML-Cu (32ng) show a partial
protection against L. mexicana in murine models. Further research is needed to increase the
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immunogenicity of this DNA vaccine. Finding the optimal concentration of ML-Cu could
improve immunogenicity of the vaccine.
6.2 Recommendations
Having the same number of mice in each group will help during the statistical analysis.
When extracting the RNA the researcher should be extremely careful and precise in order to
obtain high RNA yields, subsequently increasing cDNA yields for the QRT-PCR experiment.
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